An open label, Phase I dose escalation clinical trial of NRC-AN-019 in patients with all phases of Chronic Myeloid Leukemia, who are resistant or intolerant to Imatinib mesylate

Trial Profile

An open label, Phase I dose escalation clinical trial of NRC-AN-019 in patients with all phases of Chronic Myeloid Leukemia, who are resistant or intolerant to Imatinib mesylate

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs NRC AN 019 (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 16 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top